Skip to main content

Dexcom ratios

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026 · Market value $30.61B

In fiscal 2025 (the year to 31 Dec 2025), Dexcom had an operating margin of 19.6%, a return on equity of 34.5%, a return on invested capital of 20.8%.

From Dexcom's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Dexcom ratios, annual
USDFY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin12.3%37.9%47.1%46.6%62.6%68.0%69.3%66.0%68.5%64.4%63.1%66.4%68.6%64.7%63.2%60.5%60.1%
Operating margin−154%−93.2%−58.7%−55.8%−18.1%−8.3%−14.2%−11.1%−5.9%−18.1%9.6%15.5%10.9%13.4%16.5%14.9%19.6%
Net margin−180%−114%−58.6%−54.6%−18.6%−8.6%−14.3%−11.4%−7.0%−12.3%6.8%28.5%8.9%11.7%14.9%14.3%17.9%
Free cash flow margin−143%−102%−49.9%−42.6%−3.4%2.9%3.9%0.1%3.6%5.4%9.1%14.4%2.2%10.5%14.1%15.6%23.1%
Return on equity—−259%−54.0%−60.1%−37.0%−20.0%−31.9%−26.0%−14.3%−23.5%13.1%40.6%11.2%16.3%25.8%27.6%34.5%
Return on assets—−46.4%−35.8%−38.9%−20.0%−11.1%−18.9%−14.5%−5.1%−10.4%6.4%7.1%4.9%6.6%7.8%7.6%10.9%
Return on capital employed—−73.0%−53.4%−57.9%−32.7%−18.3%−30.9%−24.3%−8.0%−15.2%7.6%10.5%6.7%10.1%14.5%14.5%23.5%
Return on invested capital—−194%−161%−136%−58.5%−33.3%−51.1%−34.7%−16.9%−42.9%13.3%10.5%9.5%15.7%20.0%17.9%20.8%
Current ratio—4.327.113.982.903.593.462.735.367.645.475.585.111.992.841.471.88
Debt to equity———0.090.080.03—0.000.781.521.300.981.030.621.230.630.49
Net debt / EBITDA——————————3.662.64−0.85−2.08−0.24−1.240.36
Interest coverage−5.70−30.20−4072.73−278.50−32.11−26.88−142.75−91.29−3.32−8.212.3616.9214.1426.6136.4540.2763.76
Cash conversion79.2%89.9%85.2%78.2%18.5%−33.0%−27.3%−0.8%−51.8%−44.1%133%50.3%24.6%89.3%94.5%109%129%
SBC / Revenue28.2%19.3%17.7%18.4%15.4%19.3%20.6%19.3%14.8%9.9%7.0%6.2%4.6%4.3%4.2%4.2%3.4%

Quarterly

Dexcom ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin63.5%61.0%62.4%59.7%58.9%56.9%59.5%60.5%62.9%62.9%63.4%64.3%
Operating margin21.0%11.0%15.7%15.3%17.0%12.9%18.4%20.1%25.6%21.4%24.3%24.3%
Net margin24.8%15.9%14.3%13.5%13.6%10.2%15.5%23.5%21.2%16.7%19.0%20.5%
Free cash flow margin7.8%16.5%21.2%8.9%15.9%9.3%18.1%47.9%15.3%37.7%14.1%20.3%
Return on equity12.4%6.5%5.9%6.8%7.2%4.7%7.0%10.4%9.7%6.7%9.5%10.9%
Return on assets2.7%1.2%1.8%1.8%2.1%1.4%2.2%2.6%4.0%2.8%3.9%4.3%
Return on capital employed4.6%2.1%3.1%3.3%5.3%3.6%5.3%5.8%7.7%5.8%7.8%8.2%
Return on invested capital8.5%3.5%5.6%4.8%4.0%2.7%3.9%5.5%7.7%5.7%8.3%8.8%
Current ratio2.842.902.822.461.471.501.521.561.881.951.731.74
Debt to equity1.231.131.041.280.630.580.510.480.490.450.510.53
Net debt / EBITDA−0.71−0.58−2.061.26−4.10−5.910.57−1.701.080.660.620.95
Interest coverage55.6227.3241.5841.0851.0536.1455.9565.54104.19121.57144.68155.81
Cash conversion31.6%104%149%65.6%117%91.8%116%204%71.9%225%74.1%99.1%
SBC / Revenue3.6%4.2%4.5%4.4%3.9%3.3%3.9%3.7%2.8%3.6%3.0%2.7%

The main figures as JSON and plain text. See data and methodology.

DXCM in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.